Navigation Links
More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
Date:12/3/2008

st cancer, multiple myeloma) and dental status (dental extraction, periodontal disease, local trauma, including poorly fitting dentures). Many reports of ONJ involved patients with signs of local infection, including osteomyelitis. Cancer patients should maintain good oral hygiene and should have a dental examination with preventive dentistry prior to treatment with bisphosphonates. While on treatment, these patients should avoid invasive dental procedures, if possible. No data are available as to whether discontinuation of bisphosphonate therapy reduces the risk of ONJ in patients requiring dental procedures. A causal relationship between bisphosphonate use and ONJ has not been established. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit/risk assessment.

In post-marketing experience, severe and occasionally incapacitating bone, joint and/or muscle pain has been reported infrequently in patients taking bisphosphonates.

The most common adverse events (greater than or equal to 15%) in bone metastases clinical trials, regardless of causality, with Zometa 4 mg (n=1031) were as follows: bone pain (55%), nausea (46%), fatigue (39%), anemia (33%), pyrexia (32%), vomiting (32%), constipation (31%), dyspnea (27%), diarrhea (24%), weakness (24%), myalgia (23%), anorexia (22%), cough (22%), arthralgia (21%), lower-limb edema (21%), malignant neoplasm aggravated (20%), headache (19%), dizziness (excluding vertigo) (18%), insomnia (16%), decreased weight (16%), back pain (15%) and paresthesia (15%).

Caution is advised when bisphosphonates are administered with aminoglycosides, loop diuretics and potentially nephrotoxic drugs.

Zometa contains the same active ingredient as found in Reclast(R) (zoledronic acid). Patients being treated with Zometa should not be treated with Reclast.

Patients should be admi
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
4. Biodel Inc. Announces the Completion of Its Two Pivotal Trials and the Release of EASD Abstracts Containing Additional Interim Data From Its VIAject(TM) Program
5. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
6. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. New Conflict of Interest Violations Revealed at California Stem Cell Institute
9. St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia
10. Protein Tomography(TM) Reveals Molecular Mode of Action of Humax-EGFr Published in PNAS
11. Imaging Results From the ADAGIO-LIPIDS Reveal That Effects of Rimonabant on Cardiometabolic Risk Profile Include Loss of Visceral Fat and Mobilization of Liver Fat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... 16 Today, a group of national medical ... H.R. 3590, the Patient Protection and Affordable Care Act, ... its way towards a final vote in the coming ... Senators to vote against a health care bill that ... first hand that our health care system needs reform ...
(Date:12/16/2009)... MedSolutions ( www.medsolutions.com ), a leading ... two new studies highlighting the dangers of excess ... imaging tests. ,, "When used properly, CT ... said Gregg Allen, M.D., chief medical officer of ... evidence that stricter quality control measures are necessary ...
(Date:12/16/2009)... Mass., Dec. 16 According to Millennium ... technology market intelligence, although the US minimally invasive ... annual growth rate of over 12% through 2014, ... in the overall market, which previously had been ... Markets for Minimally Invasive Spine Technologies 2010 ...
Breaking Medicine Technology:Physician Groups Oppose Current Senate Health Care Reform Bill 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 2MedSolutions Applauds Renewed Focus on the Dangers of Radiation Exposure 3Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 2Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 3XLHealth Appoints New Vice President of Contracting and Provider Relations 50536 1XLHealth Appoints New Vice President of Contracting and Provider Relations 50536 2VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 1VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 2VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 3VYVANSE CII provided significant efficacy at 14 hours in adults with ADHD 50532 4New e science service could accelerate cancer research 9089 1New e science service could accelerate cancer research 9089 2
... LATHAM, N.Y., Aug. 25 Clinicians from ... Physicians in,Latham have commenced treating cancer patients using ... VAR ), an,advancement that delivers a highly-precise image-guided,intensity-modulated ... RapidArc treatments spare healthy tissue and other ...
... Studies ... Planned, COPENHAGEN, Denmark, ... in chronic lymphocytic,leukemia and non-Hodgkin,s lymphoma., Genmab A/S (OMX: GEN) announced ... and follicular,non-Hodgkin,s lymphoma (NHL) this year., "Genmab and GSK have worked ...
Other Medicine Technology:Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 2Image Guided Radiation Therapy in Latham, NY. Now Fighting Cancer Using Fast and Precise RapidArc(TM) Radiotherapy Technology 3Genmab Announces Upcoming Ofatumumab Studies 2Genmab Announces Upcoming Ofatumumab Studies 3Genmab Announces Upcoming Ofatumumab Studies 4
(Date:12/16/2009)... 16 Austin,s Custom Tops , a ... with Ryan Gray and Hill Country Home Health, a ... Wednesday, December 9th. Fifty people showed up to cheer ... through platefuls of sliders in support of the local ... as a casual bet over who could eat the ...
(Date:12/16/2009)... -- Smart Balance, Inc. (Nasdaq: SMBL ) announced ... two-year stock repurchase program of up to $25 million, ... the confidence we have in the prospects of our ... for all of our shareholders, while at the same ... Smart Balance, Inc. Chairman and Chief Executive Officer. ,, ...
(Date:12/16/2009)... Gala Raises Significant Funds to Benefit of Children with ... Christine Taylor, Gary Cole and Zachary Levi Join Ben ... LOS ANGELES, Dec. 16 At its 13th ... remarkable individuals. Hasbro President & CEO ... in recognition of his far-reaching philanthropic leadership and ...
(Date:12/16/2009)... CHEVY CHASE, Md., Dec. 16 New ... capital firm, today announced that one of its ... definitive agreement to be acquired by Ethicon, Inc., ... transaction for approximately $785 million (net of estimated ... medical technology company dedicated to designing, developing and ...
(Date:12/16/2009)... -- December 16, 2009 -- Every year in ... diagnosed, and 57,000 patients die of the disease, making ... among adults, after lung cancer. , As researchers and ... cancer -- simultaneously generating thousands of studies producing more ... and researcher of cancer and genetics at Case Western ...
Breaking Medicine News(10 mins):Health News:Austin-Based Business Co-Sponsors Gastric Feat for Charity 2Health News:Smart Balance Authorizes Stock Repurchase Program 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 2Health News:NEA-Incubated Acclarent Acquired by Johnson & Johnson's Ethicon 3Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3
... Jack Mackenroth to debut signature campaign scarf at ... NEW YORK, Nov. 7 Jack Mackenroth, from ... debuting an HIV and AIDS,education campaign called Living ... Men,s Health Crisis Fashion Forward event. At Fashion ...
... combine efforts to simplify claims and transaction ... Nov. 10 In order,to provide solutions ... for healthcare companies, Axway, recognized leader of ... quality and compliance,solutions have formed a strategic ...
... via Google Earth and,Compatibility with Polar,s Range of ... N.Y., Nov. 10 Polar (http://www.polarusa.com ),the ... technology,today introduced the RS800CX, the most advanced and ... the growing,multisport market., The RS800CX offers athletes ...
... Revenue and Gross Profit Increase, LOVELAND, Colo., ... today reported financial results for its third quarter ... Heska Corporation ("Heska" or the "Company") generated ... an increase of 21% from the,prior year period., ...
... 3 Clinical Trial For Duska,s ATPace In Planning ... Nov. 10 /PRNewswire-FirstCall/,-- Duska Therapeutics, Inc., (OTC Bulletin ... they have entered into a,preliminary agreement to collaborate ... Duska,s planned pivotal Phase 3 clinical trial in,paroxysmal ...
... Montreal Heart Institute Research,Centre Director Dr. ... trial demonstrating that VIA-2291, an investigational drug ... production,of leukotrienes, proposed mediators of vascular inflammation, ... well-tolerated with no serious,adverse events attributed to ...
Other Medicine News:Health News:'Project Runway' Designer Brings Living Positive By Design Campaign to New York to Educate About Living With HIV and Combat Stigma Associated With the Disease 2Health News:'Project Runway' Designer Brings Living Positive By Design Campaign to New York to Educate About Living With HIV and Combat Stigma Associated With the Disease 3Health News:'Project Runway' Designer Brings Living Positive By Design Campaign to New York to Educate About Living With HIV and Combat Stigma Associated With the Disease 4Health News:Axway and Edifecs Form Strategic Partnership to Benefit Healthcare Payors 2Health News:Axway and Edifecs Form Strategic Partnership to Benefit Healthcare Payors 3Health News:Polar Introduces the RS800CX Training Management System for Multisport Endurance Athletes 2Health News:Polar Introduces the RS800CX Training Management System for Multisport Endurance Athletes 3Health News:Polar Introduces the RS800CX Training Management System for Multisport Endurance Athletes 4Health News:Heska Announces Q3 2008 Results 2Health News:Heska Announces Q3 2008 Results 3Health News:Heska Announces Q3 2008 Results 4Health News:Heska Announces Q3 2008 Results 5Health News:Heska Announces Q3 2008 Results 6Health News:Heska Announces Q3 2008 Results 7Health News:Heska Announces Q3 2008 Results 8Health News:Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product 2Health News:Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product 3Health News:Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product 4Health News:Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product 5Health News:The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease 2Health News:The Results From a Clinical Trial Led by the Montreal Heart Institute Demonstrate That Drug Reduces Inflammation in Patients With Serious Cardiovascular Disease 3
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
... & Nephew ECTRA II systems permit the ... tunnel ligament endoscopically, allowing access via two ... minimizing endoscopic lens fogging with good air ... visualization and control. ECTRA knives permit the ...
Micro instruments designed to provide maximum grasping, resecting capability, and excellent maneuverability for easy access to tight, small joints (wrist, elbow, and ankle).,Features pinless hinge d...
Medicine Products: